tetano
Editor, Senior Moderator
Sci Rep
. 2024 Sep 9;14(1):21031.
doi: 10.1038/s41598-024-72086-8. To prescribe or not: a two-center retrospective observational study of antibiotics usage and outcomes of COVID-19 in Turkey
Hanife Nur Karakoc[SUP] 1 2 [/SUP], Merve Aydin[SUP] 3 [/SUP], Safiye Nur Ozcan[SUP] 4 [/SUP], Yildiz Olcar[SUP] 5 [/SUP], Esra Sumlu[SUP] 6 [/SUP], Emine Kubra Dindar[SUP] 7 [/SUP], Yusuf Kemal Arslan[SUP] 8 [/SUP], Mohammad M Sajadi[SUP] 9 [/SUP]
Affiliations
This retrospective cohort study conducted in Turkey between December 2020 and June 2022 aimed to assess antibiotic use, bacterial co-infections, and the associated factors on mortality in hospitalized patients with mild-to-severe COVID-19. Among the 445 patients, 80% received antibiotics, with fluoroquinolones being the most common choice, followed by beta-lactams and combinations. Various clinical and laboratory parameters, including symptoms, comorbidities, CCI, oxygen requirements, and CRP levels were observed to be elevated in the antibiotic group. Non-survivors had more ICU admissions and longer hospital stays compared to survivors. We conducted a multivariate Cox regression analysis to evaluate factors related to mortality. However, we did not find an association between antibiotic use and mortality [HR 2.7 (95% CI 0.4-20)]. The study identified significant factors associated with an antibiotic prescription, such as CCI (OR 1.6), CRP (OR 2.3), and ICU admission (OR 8.8), (p < 0.05). The findings suggest re-evaluating the necessity of antibiotics in COVID-19 cases based on clinical assessments, focusing on the presence of bacterial infections rather than empirical treatment. Further research is necessary to more accurately identify patients with bacterial co-infections who would benefit from antibiotic treatment.
Keywords: Antibiotic usage; Bacterial co-infections; COVID-19; Mortality; SARS-CoV-2.
. 2024 Sep 9;14(1):21031.
doi: 10.1038/s41598-024-72086-8. To prescribe or not: a two-center retrospective observational study of antibiotics usage and outcomes of COVID-19 in Turkey
Hanife Nur Karakoc[SUP] 1 2 [/SUP], Merve Aydin[SUP] 3 [/SUP], Safiye Nur Ozcan[SUP] 4 [/SUP], Yildiz Olcar[SUP] 5 [/SUP], Esra Sumlu[SUP] 6 [/SUP], Emine Kubra Dindar[SUP] 7 [/SUP], Yusuf Kemal Arslan[SUP] 8 [/SUP], Mohammad M Sajadi[SUP] 9 [/SUP]
Affiliations
- PMID: 39251674
- DOI: 10.1038/s41598-024-72086-8
This retrospective cohort study conducted in Turkey between December 2020 and June 2022 aimed to assess antibiotic use, bacterial co-infections, and the associated factors on mortality in hospitalized patients with mild-to-severe COVID-19. Among the 445 patients, 80% received antibiotics, with fluoroquinolones being the most common choice, followed by beta-lactams and combinations. Various clinical and laboratory parameters, including symptoms, comorbidities, CCI, oxygen requirements, and CRP levels were observed to be elevated in the antibiotic group. Non-survivors had more ICU admissions and longer hospital stays compared to survivors. We conducted a multivariate Cox regression analysis to evaluate factors related to mortality. However, we did not find an association between antibiotic use and mortality [HR 2.7 (95% CI 0.4-20)]. The study identified significant factors associated with an antibiotic prescription, such as CCI (OR 1.6), CRP (OR 2.3), and ICU admission (OR 8.8), (p < 0.05). The findings suggest re-evaluating the necessity of antibiotics in COVID-19 cases based on clinical assessments, focusing on the presence of bacterial infections rather than empirical treatment. Further research is necessary to more accurately identify patients with bacterial co-infections who would benefit from antibiotic treatment.
Keywords: Antibiotic usage; Bacterial co-infections; COVID-19; Mortality; SARS-CoV-2.